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ABSTRACT
Objective: To determine the outcome of patients with psychogenic pseudosyncope (PPS) after
communication of the diagnosis.
Methods: This was a retrospective cohort study of patients with PPS referred in 2007 to 2015 to
a tertiary referral center for syncope. We reviewed patient records and studied attack frequency,
factors affecting attack frequency, health care use, and quality of life using a questionnaire. We
explored influences on attack freedom and attack frequency in the 6 months before follow-up for
age, sex, education level, duration until diagnosis, probability of diagnosis, additional syncope,
and acceptance of diagnosis.
Results: Forty-seven of 57 patients with PPS could be traced, of whom 35 (74%) participated.
Twelve (34%) were attack-free for at least 6 months. The median time from diagnosis to
follow-up was 50 months (range 6–103 months). Communicating and explaining the diagnosis
resulted in immediate reduction of attack frequency (p5 0.007) from the month before diagnosis
(median one attack, range 0–156) to the month after (median one attack, range 0–16). In the
6 months before follow-up, the number of admissions decreased from 19 of 35 to 0 of 35 (p 5
0.002). The use of somatic and mental health care shifted toward the latter (p, 0.0001). Quality
of life at follow-up (Short Form Health Survey 36) showed lower scores for 7 of 8 domains
compared to matched Dutch control values; quality of life was not influenced by attack freedom.
Conclusions: After communication of the diagnosis in PPS, attack frequency decreased and
health care use shifted toward mental care. Low quality of life underlines that PPS is a serious
condition. Neurology® 2016;87:1–6
GLOSSARY
PNES 5 psychogenic nonepileptic seizures; PPS 5 psychogenic pseudosyncope; SF-36 5 Short Form Health Survey 36.
The 3 main groups of apparent transient loss of consciousness are syncope, epileptic seizures,
and psychogenic attacks.1 Psychogenic transient loss of consciousness consists of psychogenic
nonepileptic seizures (PNES), resembling epileptic seizures, and psychogenic pseudosyncope
(PPS), resembling syncope. The prevalence of PNES is 2 to 33 per 100,000 people.2 In tertiary
epilepsy clinics, PNES accounts for 20% to 30% of patients.3–5 While patients with PNES and
PPS probably have the same psychiatric disorder,6,7 they are seen by different specialties, which
may affect diagnosis, therapy, and prognosis.6
Patients with PPS typically lie immobile and unresponsive with closed eyes during attacks.
Attacks last longer and are more frequent than in syncope.8,9 The diagnosis rests on history
taking from patients and eyewitnesses and on documenting an event with a tilt table test8,9 or
home video recording.7 Such documented attacks must be recognized by patients and eye-
witnesses as the same as habitual ones.5 The diagnosis of both PPS and PNES must rest not
on exclusion but on positive evidence.5,6 The absence of PPS in large syncope series7 suggests
that PPS is not always recognized, as does the paucity of PPS research compared to PNES.8,10
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The prognosis of PNES is generally better
for those who are young, are more highly edu-
cated, and have a short delay between the first
event and the diagnosis.11–13 A comprehensive
PNES study showed that 26% of patients
receiving psychotherapy were attack-free after
42 months, with another 40% having a 50%
reduction of attack frequency.14 Follow-up
studies in PNES have shown that not only
attack frequency but also quality of life, use
of health care facilities, and employment are
important indicators.14–17 We did not find any
studies on the prognosis of PPS and therefore
studied the prognosis in a cohort of patients
with PPS, taking these aspects into account.
METHODS Patients. We searched the database of the tertiary
syncope outpatient department of the Leiden University Medical
Center from 2007 to 2015 for possible patients with PPS who
were at least 18 years old at follow-up. Patients were seen by
a neurologist (J.G.v.D.) experienced in syncope and PPS. The
diagnosis rested on history taking of patients and eyewitnesses
and on event documentation with tilt table testing, home video
recording or, rarely, home blood pressure recording. The
explanation of the nature of PPS conformed to PNES
procedures,8,9 stressing that attacks happen involuntarily, that
patients were taken seriously and were not “mad,” and that the
attacks signaled an underlying psychological problem. Terms
such as psychological were used and not avoided. Patients were
seen after 1 or 2 weeks to repeat the explanation, to address
questions, and to discuss therapeutic options. If attacks did not
resolve, patients received advice to seek psychiatric or
psychological help. Because patients came from a wide area, the
choice of a suitable therapist was left to their general practitioner
or the referring specialist. In earlier years, contact was ended after
psychiatric therapy was advocated, but later, contact was
maintained until psychotherapy was underway.18
Standard protocol approvals, registrations, and patient
consents. The study protocol was approved by the local institu-
tional review ethics board.We sent potential participants an infor-
mational letter and asked them to fill in a questionnaire on paper or
online. Two authors (D.P.S. and M.J.O.) contacted patients by
telephone to provide additional information and to encourage
a response until patients completed the questionnaire or further
attempts seemed futile. All participants gave informed consent.
Patient inclusion. Three authors (D.P.S., R.D.T., and J.G.v.D.)
studied case records using diagnostic criteria adapted from PNES
criteria6; the adaptation meant that we ignored interictal EEG
findings and in their place stressed ictal heart rate and blood pres-
sure. The history had to contain positive features of PPS such as
closed eyes during attacks, a long duration, and high frequency.7
Attack documentation required recording an event recognized as
typical by patients or relatives during a tilt table test, comprising
continuous blood pressure, ECG, EEG, and video,8,9,19 or ictal
home video or blood pressure recording. Patients with a positive
history and attack documentation were classified as definite; those
with a positive history without documentation were classified as
probable. The final inclusion criterion was that the diagnosis had
been explained as stated above.
Study data. The following information was noted: age, sex, fre-
quency of events in 1 month both before and after diagnosis,
duration from the first PPS attack until diagnosis, the additional
presence of syncope, earlier consultation of medical specialists and
psychologists, and hospital admission or emergency department
visits for these attacks.
The questionnaire asked for duration since last attack and
attack frequency in the last week, month, and 6 months. We
defined attack-free as no attack in the last 6 months. Questions
addressing health care use included frequency of visits to general
practitioners, emergency departments, medical specialists, and
psychologists and the number of admissions for PPS in the last
6 months before follow-up.
We investigated patients’ reception of the diagnosis, asking
whether patients had felt that they were treated with respect,
whether they had felt offended by the psychological nature of
attacks, and whether they agreed with the explanation at the time
of diagnosis and at follow-up, all of which were noted as “agree,”
“no opinion,” and “disagree.”
Other questions concerned marital status, housing situation,
education level, and employment. We used the Dutch version of
the Short Form Health Survey 36 (SF-36) to assess quality of
life.20
Data analysis. We compared baseline variables between partic-
ipants, i.e., those who completed the questionnaire, and nonpar-
ticipants, who did not. Because attack frequency and various
other variables had skewed distributions, we favored nonparamet-
ric analyses. We examined an immediate effect of diagnosing PPS
on attack frequency by comparing attack frequency in the months
before and after explanation of the diagnosis. The main analysis of
attack frequency concerned a comparison between the number of
attacks in the month before diagnosis and that in the month
before follow-up using the Wilcoxon paired signed-rank test
and between the proportions of participants who were attack-
free and those who were not attack-free using the Fisher exact test.
We explored influences on attack frequency in the 6 months
before follow-up and on attack freedom for age, sex, education
level, and duration until diagnosis; probability of diagnosis; the
presence of syncope; and the reception of the diagnosis. To ana-
lyze effects on attack frequency, we used the Spearman r for
quantitative variables (e.g., age, duration until diagnosis) and
the Mann-Whitney test for dichotomous variables (e.g., sex).
To analyze effects on attack freedom (yes/no), we used the
Mann-Whitney, x2, and Fisher exact tests.
Answers concerning reception of the diagnosis were dichoto-
mized into disagree and agree, ignoring the category no opinion.
We compared somatic and mental health care use before and 6
months after diagnosis. We compared the subset of patients of
working age (25–65 years) to 2015 employment data from Statis-
tics Netherlands (www.CBS.nl). We compared the expected num-
ber of patients not working to the actual number not working,
taking into account the patient group’s age and sex composition
(Fisher exact test).
We compared the 8 domains of the SF-36 to published
Dutch control values, taking age and sex into account.20 We
calculated individual patient z scores per domain by first cal-
culating the difference between a patient value and the control
group mean for the correct sex and age group and then dividing
that by the control group’s SD. We used the Student t test to
investigate whether mean patient z scores differed from zero,
i.e., whether their mean scores differed from age- and sex-
corrected control values. We also compared mean z scores
per domain between the groups that were attack-free and not
attack-free.
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No attempts were made to impute any missing data. We used
SPSS-20 and Matlab for statistical analysis. A significance thresh-
old of p , 0.01 was used.
RESULTS Baseline data. Participants and nonpartici-
pants. Fifty-seven potential participants fulfilled PPS
criteria (48 definite, 9 probable). Ten patients were lost
to follow-up. Of the remaining 47 patients, 12
(25.5%) did not reply (figure 1), leaving 35 partici-
pants. The participant and nonparticipant groups did
not differ in age, sex, and attack frequency in the
month before diagnosis; duration until diagnosis; and
probability of the diagnosis (table 1).
Participant baseline data. Most participants were
female (24 of 35, 69%). The median age was 36 years
(range 14–74 years). The median delay to diagnosis
was 24 months (range 0–288). Almost all patients (33
of 35, 94%) had a definite diagnosis of PPS; 2 had
probable PPS. The median attack frequency in the
month before diagnosis was 2 (range 0–16).
Health care use. Patients had on average each seen
1.49 somatic specialties and 0.14 mental health care
providers (i.e., a psychologist or psychiatrist) in the
6 months before diagnosis. The number of previous
admissions for PPS was unknown in 5 patients; of
the remaining 30 patients, 19 (54%) had been admit-
ted in the year before diagnosis.
Follow-up analysis. Attack frequency. Data on attack fre-
quency in the first month after diagnosis were avail-
able for 21 patients. Their median frequency had
decreased (p 5 0.007) from the month before diag-
nosis (median 1, range 0–156; mean 4.0 1 4.9
attacks) to the month after (median 1, range 0–16;
mean 1.7 1 3.5).
The median time from diagnosis to follow-up was
50 months (range 6–103 months). The median
attack frequency in the last month of follow-up was
0 attacks per month (range 0–35), which was lower
than in the month before diagnosis (p 5 0.006). At
follow-up, 12 patients were attack-free.
Factors affecting attack frequency. Age did not influ-
ence attack frequency in the last 6 months of
follow-up (p 5 0.9) and did not differ between those
who were attack-free and those who were not (p 5
0.25). Likewise, sex affected neither attack frequency
(p 5 0.33) nor attack freedom (p 5 1.0). Education
level did not affect attack frequency (p 5 0.9) or
attack freedom (p 5 0.14). The duration between
the first attack and diagnosis did not affect attack
frequency (p 5 0.74) or attack freedom (p 5 0.33).
This also held for the presence of syncope, both for
attack frequency (p 5 0.66) and for attack freedom
(p 5 1.0).
Reception of the diagnosis.Most patients felt that they
had been treated respectfully: 29 agreed (83%), 3 dis-
agreed, and 3 had no opinion. Eight had felt of-
fended, 22 had not, while 5 had no opinion.
Fifteen agreed with the psychological explanation at
the time of diagnosis, while 13 did not, with 7 having
no opinion. At follow-up, 18 agreed, 11 did not,
while 6 neither agreed nor disagreed. We used the
dichotomized form of these answers to explore a rela-
tion with attack frequency and attack freedom and
found no effects. For example, of the 18 who agreed
at follow-up that their attacks had a psychological




(n 5 12) p Value
Median age (range), y 36.0 (14–74) 35.0 (17–59) 0.92 (M-W)
Sex, M:F 11:24 2:10 0.46 (FET)
Median attack frequency in 1 mo before diagnosis (range) 2.0 (0–16) 1.0 (0–10) 0.33 (M-W)
Probability of diagnosis (definite, probable), n 33, 2 9, 3 0.062 (x2)
Median duration until diagnosis (range), mo 24.0 (0–288) 42.0 (0–216) 0.33 (M-W)
Abbreviations: FET 5 Fisher exact test; M-W 5 Mann-Whitney test.
Figure 1 Flowchart explaining the number of
subjects
PPS 5 psychogenic pseudosyncope.
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explanation, 11 were not attack-free, compared with
8 of 11 who did not agree (p 5 0.4).
Health care use. No patient had visited an emer-
gency department or had been admitted for PPS in
the 6 months before follow-up. This differed from
the year before diagnosis (19 of 35 admissions) after
correction for the difference in duration of the periods
(Fisher exact test, p 5 0.002).
In the year before diagnosis, patients had together
seen 52 somatic specialists and 5 mental health care
providers (psychologists or psychiatrists), 57 health
care providers in all. Corresponding numbers in the
6 months before follow-up were 6 and 14, i.e., 20
health care providers in all. After correction for the
difference in duration, the proportion of somatic to
mental health care providers had shifted over time
toward more mental health care use (p , 0.0001).
Social status and employment.The number of patients
who were married or having a relationship was the
same before diagnosis and at follow-up (24 of 35,
69%). At follow-up, 9 of 24 patients of working
age did not work. The expected unemployment rate
for a group with this age and sex composition was
7.0%, leading to an expected number of patients
not working of 1.67. After this number was rounded
to 2, the actual proportion of those not working and
working (9:15) was compared to the expected propor-
tion (2:22). Although more patients did not work
than expected, this difference was not significant
(p 5 0.036).
Quality of life (SF-36). Because of an entry error, the
last 4 questions concerning the general health domain
were missing from the online version (n5 19) of the
questionnaire. Quality of life is shown in tables 2 and
3. Patient scores differed for 7 of the 8 domains from
Dutch normal values corrected for age and sex. Mean
domain scores did not differ between patients who
were attack-free and those who were not attack-free,
although values were worse for those who were not
attack-free for all 8 domains (figure 2).
DISCUSSION The main result of this first PPS
follow-up study was a reduction in the number of
attacks, expressed both as attack frequency and as
attack freedom: at the follow-up of .4 years, one-
third (12 of 35) were attack-free. Other important
findings were that conveying the diagnosis resulted in
an immediate decrease in attacks in the first month
after diagnosis. At follow-up, the number of hospital
admissions had decreased and the nature of health care
use had shifted from somatic to mental health care.
Patients tended to have a higher-than-expected
unemployment rate. Quality of life was low for both
those who were attack-free and those who were not.
The positive effects in our study are largely in line
with PNES studies showing that a clear explanation
may lead to a reduction of attacks13,21–23 and a reduc-
tion of emergency service use.13 We confirm that
communication of the diagnosis can cause an imme-
diate reduction of attack frequency.13,24,25 Fifty-seven
percent had syncope besides PPS, conforming to
PNES results, in which 10% to 30% of patients also
have epilepsy. The incidence of syncope among pa-
tients with PPS seems higher than that of epilepsy
among patients with PNES, possibly because syncope
is much more prevalent than epilepsy.
The analysis did not reveal some relations reported
for PNES such as a poor prognosis for those with a long
duration between the first attack and diagnosis.11,24,26
This might be due to the relatively short duration in
Table 2 Quality of life (SF-36)
Domain Patients
Corrected
normal Difference z Score t Test, p value
Physical functioning 68.4 6 29.4 86.5 218.1 6 26.5 21.15 6 1.71 0.0004
Role physical 50.0 6 44.6 79.1 229.0 6 42.9 20.94 6 1.47 0.0006
Role emotional 65.7 6 46.1 81.5 215.8 6 45.9 20.51 6 1.42 0.0406
Vitality (energy) 46.0 6 24.8 67.9 221.9 6 24.3 21.22 6 1.36 ,0.0001
Mental health 60.0 6 25.6 76.0 216.0 6 25.9 21.04 6 1.63 0.0006
Social functioning 54.3 6 27.8 84.9 230.6 6 27.2 21.51 6 1.41 ,0.0001
General health 41.3 6 25.4 72.5 231.1 6 23.3 21.65 6 1.27 ,0.0001
Body pain 54.0 6 31.2 75.3 221.3 6 30.6 21.00 6 1.50 0.0004
Abbreviation: SF-36 5 Short Form Health Survey 36.
Mean values (SD) are given for the 8 domains of the SF-36 questionnaire. All domains range from 0 to 100, with higher
values for better quality of life. Corrected normal shows the mean values of a hypothetical group in which each participant
had the same age and sex as the patient group but whose value for each domain represents the mean of the control value
for that age and sex: it represents age- and sex-corrected normal values. Difference represents mean group differences
from control values, and z scores represent how much patient values differ from control values in units of SD of control
values. The p values show whether mean z scores differ from zero. For 7 domains, patients have lower quality of life than
controls.
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our PPS group: the median duration was 24 months
(mean 46 months), contrasting with the typically lon-
ger mean duration for PNES of 6 to 7 years.13 We did
not find a worse prognosis for higher age11,27 or for
women.13 We suspect that the lack of these relations
represents sampling effects because such relations are
not universally found in PNES either. We also did not
find a relation between how well the diagnosis was
received and attack frequency. Intriguingly, this also
held for the question of whether patients accepted the
psychological nature of PPS. Hence, acceptance of the
psychological nature does not seem to be a prerequisite
for attack freedom, nor does its absence imply that
attacks must continue.
The number of admissions decreased, and health
care use shifted from somatic to psychiatric care.
The rate of unemployment did not differ from Dutch
values corrected for age and sex but was higher
(37.5%) than expected (7%). The lack of significance
is probably due to the restriction to those of working
age, reducing the sample size of the remaining group
(n 5 24).
Quality of life was remarkably poor compared to
sex- and age-matched Dutch control data. Quality
of life was not higher in those who were attack-free
than in those who were not. The overall poor quality
of life and lack of a clear relation with attack freedom
suggest that the underlying psychological problems
impair quality of life more than the mere presence
of attacks. This emphasizes the opinion derived from
PNES studies that attack frequency should not be the
sole parameter of follow-up; quality of life may well
be the most relevant outcome parameter.
The study contained no control group and took
place in a tertiary referral center, with a likely bias
toward difficult cases and, presumably for that reason,
a high rate of PPS (8%–10% of cases). We had made
no attempt to standardize psychological treatment
because patients came from across the Netherlands,
making long-term treatment in our hospital imprac-
tical. Hence, only the diagnostic process, explanation
of the diagnosis, and early follow-up were standard-
ized. The lack of a standardized treatment may have
impaired treatment efficacy.
The low quality of life emphasizes that PPS repre-
sents a considerable burden to patients. Although we
did not aim to calculate the burden to society, our re-
sults concerning employment and medical consump-
tion suggest that that burden also is considerable. At
follow-up, attack frequency was reduced, and there
was a shift away from somatic to psychiatric health
care use. The outcome may well be worse for patients
with PPS who remain undiagnosed or who are not
directed to psychiatric health care.
We feel that all those diagnosing syncope should
be aware of PPS, in particular those working in ded-
icated syncope units.28 Much like specialized epilepsy
units attract a concentration of patients with PNES,
so a high rate of PPS is a corollary of tertiary syncope
care. Neurologists and cardiologists who see patients
with PPS may tend to shy away from communicating
a psychiatric diagnosis out of fear of offending pa-
tients. In this study, words such as psychological were
consistently used, yet the vast majority of patients
(83%) felt that they were treated with respect. This
suggests that this fear is not warranted, provided that
adequate time is taken to communicate the diagnosis.
Hence, we urge somatic specialists seeing patients
Figure 2 Attack freedom and quality of life
The 8 domains of the Short Form Health Survey 36 (SF-36) are shown for those who were
and whowere not attack-free. The horizontal dotted lines above the bars indicate normal val-
ues per domain corrected for age and sex. Vertical bars indicate mean values for those who
were not attack-free (n 5 23) and those who were attack-free (n 5 12). Vertical lines show
standard errors. Horizontal bold lines indicate the mean value per domain for the entire
psychogenic pseudosyncope (PPS) group (n 5 35). BP 5 body pain; GH 5 general health;
MH 5 mental health (emotional wellbeing); PF 5 physical functioning; RE 5 role emotional;
RP 5 role physical; SF 5 social functioning; VT 5 vitality (energy).








Physical functioning 61.3 6 30.4 82.1 6 22.8 0.107
Role physical 41.3 6 43.7 66.7 6 43.1 0.196
Role emotional 63.8 6 47.0 69.4 6 46.0 0.871
Vitality (energy) 40.7 6 25.9 56.3 6 19.9 0.176
Mental health 55.7 6 25.2 68.3 6 25.3 0.290
Social functioning 51.1 6 28.9 60.4 6 25.5 0.616
General health 36.9 6 24.7 49.8 6 25.6 0.311
Body pain 47.8 6 30.6 65.8 6 30.0 0.313
Mean values for the group that was attack-free and the group that was not attack-free are
shown for all 8 Short Form Health Survey 36 domains. The p value represents results of a t
test. Although mean values were lower for the group that continued to have attacks for all
domains, none of the differences were significant.
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with PPS to overcome their reticence in communi-
cating the diagnosis because otherwise they are likely
to do their patients a disservice.
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